Tilray Shares Surge on Political Shift and European Expansion

Tilray Brands, a leading cannabis company, witnessed an extraordinary trading session yesterday as its stock value skyrocketed by 60.87 percent to close at $1.85. During the day’s trading, the equity even reached an unprecedented intraday peak of $1.86. This dramatic upward movement was fueled by a surprising development in U.S. drug policy combined with the firm’s strategic initiatives to grow its presence in the European market.

Policy Shift and Financial Performance

The primary driver behind the stock’s powerful rally was an unexpected announcement from former President Donald Trump. In a detailed video presentation lasting nearly three minutes, he advocated for the health benefits of cannabis for older adults and called for Medicare to cover hemp-derived CBD products. Trump characterized this proposal as potentially “the most significant senior health initiative of the century,” highlighting the body’s endocannabinoid system and explaining how plant-based CBD could alleviate pain, enhance sleep quality, and improve overall well-being.

Adding considerable weight to this shift, the current administration is actively reviewing a proposal to reclassify marijuana from a Schedule I to a Schedule III controlled substance. Supporting this move, Trump referenced a PricewaterhouseCoopers analysis that projects annual healthcare savings of $64 billion with the full integration of cannabis into medical practice.

Despite the impressive stock performance, Tilray’s fundamental financial metrics reveal ongoing challenges. For fiscal 2025, the company posted revenue of $821 million; however, it continued to report losses, with a net loss per share of $2.31. Its liquidity position, comprising $248 million in cash and marketable securities, provides some operational flexibility. Nevertheless, persistent trading below $1 raises concerns about potential Nasdaq listing compliance issues, which might necessitate a reverse stock split. Market participants are keenly awaiting the quarterly report scheduled for October 9th for signs that the company can convert political momentum into sustained profitability.

Should investors sell immediately? Or is it worth buying Tilray?

Strategic Moves in Europe

Concurrent with the political developments, Tilray actively contributed to the positive sentiment by announcing a significant expansion of its premium medical cannabis production. The company is scaling up operations at its EU-GMP certified facility located in Neumünster, Germany. This expansion includes the introduction of five new craft cannabis flower products to the country’s federal cultivation program, managed by the Federal Institute for Drugs and Medical Devices (BfArM).

These new offerings are notable for their high potency, with THC concentrations ranging from 22% to 30%, specifically designed to meet the needs of patients requiring substantial therapeutic intervention. Rajnish Ohri, Managing Director of International operations, reinforced the company’s commitment to supplying “high-quality, EU-GMP certified medical cannabis options” to the German market.

Market Reaction and Sector Impact

The euphoria, however, proved to be somewhat transient. In pre-market trading the following day, Tilray’s stock had already retreated by 5.4% to $1.75. This price volatility is characteristic of the cannabis sector, where equities are known for their sharp reactions to political news and regulatory signals. The intensity of the trading activity was underscored by a massive volume exceeding 371 million shares.

The positive sentiment also spilled over to other companies within the industry. Peers such as Canopy Growth and Aurora Cannabis also experienced gains, though their performances were notably less spectacular than the surge seen in Tilray shares. This event underscores the highly speculative and news-driven nature of investing in the cannabis market.